Latest Share Trading News

Lotus Resources has secured A$34.2 million from institutional investors in a fully underwritten entitlement offer, with a retail component set to raise an additional A$26 million. The funds aim to support the Kayelekera uranium project’s production ramp-up and financial stability.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Lodestar Minerals has responded to an ASX query over the late filing of director interest notices, attributing the delay to an administrative oversight during an option conversion process. The company has updated its procedures to prevent future lapses.

Beacon Minerals delivered steady gold output of 5,241 ounces in Q2 2026 at its Jaurdi Gold Project, alongside a fully franked cash dividend and a significant in-specie distribution of Forrestania Resources shares to shareholders.

Resimac Group Ltd (ASX:RMC) has explained the late filing of a director’s change of interest notice as an administrative oversight and plans refresher training to reinforce compliance.

Larvotto Resources rejects Austral Resources' non-binding bid for Hammer Metals, underscoring its binding scheme and operational strengths including imminent production at Hillgrove.

The Supreme Court of New South Wales has approved the scheme of arrangement for Rubik Australia to acquire Qube Holdings, setting the stage for trading suspension and ownership transfer.

Sabre Resources (ASX:SBR) has lodged a prospectus offering up to 530 million new options, aiming to clear trading restrictions and raise capital for exploration and acquisitions.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

Whitefield Industrials delivered a $21.1 million net profit for FY2026, upheld its long-standing dividend track record, and outperformed its benchmark despite geopolitical tensions and market volatility.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Future Generation Global Limited (ASX:FGG) has updated its special dividend details for the six months ending December 2025, confirming a fully franked 3-cent payout and outlining its dividend reinvestment plan pricing.